Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_assertion type Assertion NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_head.
- NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_assertion description "[Primary screening with HC2 generally detects 23% (95% confidence interval, CI: 13-23%) more CIN-2, CIN-3, or cancer compared to cytology at cut-off atypical squamous cells of undetermined significance (ASCUS) or LSIL, but is 6% (95% CI: 4-8%) less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_provenance.
- NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_assertion evidence source_evidence_literature NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_provenance.
- NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_assertion SIO_000772 16950021 NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_provenance.
- NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_assertion wasDerivedFrom befree-20140225 NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_provenance.
- NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_assertion wasGeneratedBy ECO_0000203 NP798372.RAzD9KBS5lA7ZpvvXps4VpOi8BcXCWqwSyFJRSeDpNmkY130_provenance.